| mRNA |
tivozanib |
CTRPv2 |
pan-cancer |
AAC |
0.0036 |
0.9 |
| mRNA |
NSC632839 |
CTRPv2 |
pan-cancer |
AAC |
0.0032 |
0.9 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0031 |
0.9 |
| mRNA |
neratinib |
CTRPv2 |
pan-cancer |
AAC |
0.0034 |
0.9 |
| mRNA |
ML320 |
CTRPv2 |
pan-cancer |
AAC |
-0.0033 |
0.9 |
| mRNA |
OSI-930 |
CTRPv2 |
pan-cancer |
AAC |
0.0034 |
0.9 |
| mRNA |
selumetinib:UNC0638 (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0032 |
0.9 |
| mRNA |
SR1001 |
CTRPv2 |
pan-cancer |
AAC |
0.0034 |
0.9 |
| mRNA |
WZ8040 |
CTRPv2 |
pan-cancer |
AAC |
0.0034 |
0.9 |
| mRNA |
BRD-K30748066 |
CTRPv2 |
pan-cancer |
AAC |
0.01 |
0.9 |